We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WONDFO

Wondfo is a high-tech biological company focusing providing professional products and services for rapid diagnosis an... read more Featured Products: More products

Download Mobile App





Wondfo Exhibits Newly-Launched Time-Resolved Fluorescence Immunoassay Analyzers

By LabMedica International staff writers
Posted on 23 Jul 2023

Wondfo (Guangzhou, China) is providing a glimpse of its several newly-launched products alongside its flagship products at AACC 2023. More...

Wondfo's flagship products being highlighted at the show include the Finecare FIA Meters (FS-114/FS-205), Accre CLIA Analyzer (A90), and Blood Gas Analyzer (BGA-102). The Finecare FIA Meter Ⅱ Plus SE (FS-114) is intended for use by healthcare professionals to improve diagnosis and monitoring of various conditions, including COVID-19, diabetes, renal injury, cardiovascular disease, pregnancy, inflammation, tumor, etc. The Finecare FIA Meter III Plus (FS-205) is a fluorescence immunochromatographic semi-automatic analyzing system with internal temperature control. It can test 20 items at the same time and help diagnose conditions such as infection, diabetes, cardiovascular diseases, renal injury, hormone, etc.

Accre 90 is a compact automatic bench-top chemiluminescence immunoassay (CLIA) analyzer. With a single-dose reagent cartridge, it allows 600 days MTBF, requiring no extra consumables. It offers both simple operation, and a reliable calibration & quality control system. Wondfo's Blood Gas Analyzer (BGA-102) is used with its blood gas test cartridge (electrochemistry) to measure a patient's pH balance, pCO2, pO2, Na+, K+, Ca2+, Cl–, Hct, Lac, and Glu. Among its newly-launched products highlighted at AACC 2023 were the new FS-1000 and FS-2000 fluorescence immunoassay analyzers which offer improved specificity, sensitivity, repeatability, stability, and faster results in 3-8 minutes.

At the Wondfo AACC 2023 booth, Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) is showcasing the RYAN, the "next generation" of fentanyl testing. RYAN is a portable fluorescence instrument that can be used in a laboratory or point-of-care setting with the Fentanyl Urine Detection Kit which is the first ever FDA-cleared and CLIA-categorized point-of-care fentanyl test. This fluorescence immunoassay is intended for the qualitative detection of fentanyl in human urine at a cutoff concentration of 1.0 ng/mL.

Related Links:
Wondfo 
Carolina Liquid Chemistries


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
POC Immunoassay Analyzer
Procise DX
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new CRISPR-based technique enables simultaneous detection of multiple pathogens in a single test (photo courtesy of Shutterstock)

CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously

Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.